Indication

For the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

Medicine details

Medicine name:
melatonin (Slenyto)
SMC ID:
SMC2306
Pharmaceutical company
Flynn Pharma Ltd
BNF chapter
Central nervous system
Submission type
Resubmission
Publication due date:
11 January 2021
SMC meeting date:
01 December 2020
Patient group submission deadline:
02 November 2020